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Abstract
Background: Long-lasting and sterile protective immunity against Plasmodium falciparum can be achieved by
immunization of malaria-naive human volunteers under chloroquine prophylaxis with sporozoites delivered by
mosquito bites (CPS-immunization). Protection is mediated by sporozoite/liver-stage immunity. In this study, the
capacity of CPS-induced antibodies to interfere with sporozoite functionality and development was explored.
Methods: IgG was purified from plasma samples obtained before and after CPS-immunization from two separate
clinical trials. The functionality of these antibodies was assessed in vitro in gliding and human hepatocyte traversal
assays, and in vivo in a human liver-chimeric mouse model.
Results: Whereas pre-treatment of sporozoites with 2 mg/ml IgG in the majority of the volunteers did not have
an effect on in vitro sporozoite gliding motility, CPS-induced IgG showed a distinct inhibitory effect in the
sporozoite in vitro traversal assay. Pre-treatment of P. falciparum sporozoites with post-immunization IgG significantly
inhibited sporozoite traversal through hepatocytes in 9/9 samples when using 10 and 1 mg/ml IgG, and was
dose-dependent, resulting in an average 16% and 37% reduction with 1 mg/ml IgG (p = 0.003) and 10 mg/ml
IgG (p = 0.002), respectively. In vivo, CPS-induced IgG reduced liver-stage infection and/or development after a
mosquito infection in the human liver-chimeric mouse model by 91.05% when comparing 11 mice receiving
post-immunization IgG to 11 mice receiving pre-immunization IgG (p = 0.0008).
Conclusions: It is demonstrated for the first time that CPS-immunization induces functional antibodies against
P. falciparum sporozoites, which are able to reduce parasite-host cell interaction by inhibiting parasite traversal
and liver-stage infection. These data highlight the functional contribution of antibody responses to pre-erythrocytic
immunity after whole-parasite immunization against P. falciparum malaria.
Keywords: Malaria, Plasmodium falciparum, Sporozoites, Liver-stage, Immunization, CPS, CHMI, Inhibitory antibodies,
Human liver-uPA-SCID mouse model
Background
Malaria is caused by mosquito-transmitted protozoan
Plasmodium falciparum parasites with a complex multi-
stage life cycle in the human host. When P. falciparum-in-
fected Anopheles mosquitoes probe for blood, sporozoites
are deposited in the skin, move by circular locomotion
(gliding) [1], and traverse cell barriers by breaching host
cell membranes [2]. When sporozoites have reached
the liver via the blood circulation, they first cross the
sinusoidal barrier, traverse through and eventually invade
hepatocytes [2,3]. Previous studies have demonstrated the
importance of P. falciparum sporozoite gliding motility
for invasion of a hepatocyte [4,5]. Moreover, cell traversal
has been shown to be important for the progression
of sporozoites to the liver and thus, enhancement of
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successful infection [3,6-8]. Subsequent liver-stage de-
velopment is completed by merozoite release into the
bloodstream and invasion of erythrocytes (asexual blood-
stages) [9].
Immunity against malaria can be naturally acquired in
individuals living in malaria-endemic areas, however,
only after continuous exposure to the parasite, and
appears to wane in the absence of ongoing P. falciparum
exposure [10]. Historic passive transfer studies have
demonstrated a key role for antibodies in controlling
blood-stage parasites during natural P. falciparum infec-
tion and reducing clinical symptoms of malaria [11-13],
as confirmed in animal models of malaria [14-16].
Although antibodies are crucial in controlling blood-
stages, naturally acquired immunity never results in
complete parasite elimination.
Generating long-lasting and sterilizing immunity
against malaria with pre-erythrocytic subunit vaccines,
has only had limited success. The RTS,S subunit vaccine,
to date the only most advanced malaria vaccine candidate
tested in Phase III clinical trials, is based on P. falciparum
circumsporozoite protein (CSP), a major sporozoite sur-
face protein [17]. The RTS,S vaccine has been shown to
elicit strong CSP-specific antibodies and to induce protec-
tion in the majority of the volunteers in a CHMI model
upon infectious mosquito bite challenge [18-21]. However,
4/5 and 5/9 protected volunteers developed delayed
parasitaemia upon re-challenge with infectious mos-
quito bites ~ six or five months after the initial challenge,
respectively [21,22]. Additionally, RTS,S vaccination only
confers modest protection in the field [23-26]. Immu-
nization with other subunit vaccines, for instance with the
sporozoite surface protein 2 (a homolog for P. falciparum
thrombospondin-related adhesion protein (TRAP)) which
is expressed on both the surface of sporozoites [27,28] and
within infected hepatocytes [28], induced only partial pro-
tection in mice, but complete protection when given
together with CSP [29]. However, Phase I/IIa clinical trials
in which humans were immunized with RTS, S/TRAP
failed to provide protection in the majority of volun-
teers (unpublished data, as written by [30]). Moreover,
immunization of humans with a recombinant liver-
stage antigen-1 (LSA-1)-based vaccine elicited high anti-
body titers, but did also not protect against P. falciparum
infection [31].
While the induction of sterile immunity with subunit
vaccines has been shown to be difficult, sterile immunity
against malaria can be achieved experimentally by
whole-parasite immunization with attenuated sporozo-
ites in animal models and human volunteers, targeting
the sporozoite/liver-stage parasites (pre-erythrocytic
stages). As early as the 1960s, it was shown that sterile
protective immunity can be induced in animals and
humans by immunization with Plasmodium sporozoites
attenuated by gamma irradiation (RAS) and delivered by
P. falciparum-infected mosquito bites [32-34]. Sera from
RAS-immunized subjects were able to reduce sporozoite
invasion into hepatocytes, as shown in both animal
[35,36] and human models of malaria [37-39]. This im-
munization approach, however, requires a minimum of
1,000 bites from irradiated mosquitoes to induce steri-
lizing immunity in humans. Therefore, more studies to
other potential immunization methods have been con-
ducted. Very recently, it has been demonstrated that
intravenous immunization of humans with a radiation-
attenuated and cryopreserved P. falciparum sporozoite
vaccine can also induce protection against P. falciparum
malaria [40]. In vitro invasion experiments with hepatoma
cells and sera from volunteers protected after 4–5 im-
munization doses revealed that immunization-induced
antibodies were able to inhibit in vitro sporozoite invasion
[40]. However, to circumvent the need for irradiation of
parasites, another whole-parasite vaccination approach
has been developed, to be specific the genetically engi-
neered and attenuated parasites (GAP). Passive immu-
nization of naive mice with pooled serum from mice
immunized i.v. with Plasmodium yoelii-GAP one day
before mosquito bite challenge, reduced the liver parasite
burden by 48 hours after infection [41]. Exposure of
human volunteers to ~5 bites from mosquitoes infected
with a first generation of P. falciparum GAP (PfGAP),
followed by a high-dose exposure to ~200 PfGAP-infected
mosquito bites, led to breakthrough infection in one out
of six volunteers, consisting of breakthrough PfGAP-para-
sites [42]. While this Phase I study was not safe and
therefore not successful, plasma from volunteers ob-
tained three months after high-dose exposure could
efficiently block in vitro hepatoma cell invasion by P.
falciparum sporozoites [43].
Next to the RAS and GAP whole-parasite vaccination
approaches, a highly efficient immunization regimen
based on controlled human malaria infection (CHMI)
that induces long-lasting sterile immunity in malaria-naive
individuals has recently been established: volunteers are
exposed to ~45 wild type P. falciparum-infected mosquito
bites, while receiving a prophylactic regimen of chloro-
quine (ChemoProphylaxis and Sporozoites, CPS) [44,45].
CPS-immunization allows full liver-stage maturation
and development of early asexual blood-stage parasites,
however, it induces protection specifically targeting
pre-erythrocytic, but not blood-stages [46]. In previ-
ous CPS-immunization studies, cellular responses to
both blood-stage parasites and sporozoites were found
[45,47]. Antibodies targeting the cell-free sporozoites may
interfere with migration and invasion of hepatocytes, and
thus lower the initial liver parasite load and complement
T-cell mediated protection. Analysis of antibody responses
by P. falciparum protein-microarray identified two pre-
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erythrocytic antigens i.e. CSP and LSA-1 as the two pro-
teins predominantly recognized after CPS-immunization
[48]. Moreover, efficient induction of memory B-cells and
antibodies was found to classical pre-erythrocytic anti-
gens, to be specific CSP and LSA-1 (Nahrendorf and
Scholzen et al., manuscript in preparation). While the
induction of antibodies by CPS-immunization has been
demonstrated, their functional activity against sporozoite/
liver-stage parasites has not yet been established. This
study, therefore, focused on the possible functional con-
tribution of antibodies to pre-erythrocytic protective im-
munity after CPS-immunization.
Methods
Study design and plasma sample collection
Citrated plasma samples were collected during two clin-
ical CPS-immunization trials approved by the Central
Committee for Research Involving Human Subjects of
The Netherlands (Study 1 [44], ClinicalTrials.gov num-
ber NCT00442377; CCMO NL24193.091.09, and Study
2 [46], ClinicalTrials.gov number NCT01236612; CCMO
NL34273.091.10). In both studies, healthy malaria-naive
Dutch volunteers were immunized three times at
monthly intervals by exposure to 12–15 P. falciparum-
infected mosquito bites, while receiving chloroquine
prophylaxis. All subjects provided written informed con-
sent before screening and the study team complied with
the Declaration of Helsinki and Good Clinical Practice.
The following plasma samples, collected before (pre)
and after CPS-immunization (post), were selected for
IgG purification based on availability: ten volunteers
from Study 1 and three from Study 2 protected against
sporozoite challenge infection and another three volun-
teers from Study 2 challenged with blood-stages. For the
latter three, their protection status upon sporozoite
challenge is therefore unknown.
IgG purification from citrated plasma samples
IgG purification from 3–8 ml plasma samples was
performed using a 5 ml HiTrap Protein G HP column
(Amersham Biosciences) according to manufacturer’s in-
structions and IgG was taken up in phosphate buffered
saline (PBS, GIBCO). IgG concentrations were deter-
mined by a NanoDrop spectrophotometer (NanoDrop
Technologies, NanoDrop program 1000 version 3.8.2.).
For Study 1, due to limited plasma availability, IgG
samples from two volunteers each were pooled, resulting
in five pools of two volunteers. For Study 2, IgG samples
from six individual CPS-immunized volunteers were
available.
Generation of P. falciparum sporozoites
Plasmodium falciparum NF54 asexual and sexual blood
stages were cultured in a semi-automated culture system
[49-51]. Sporozoites were produced by feeding female
Anopheles stephensi mosquitoes using standard mem-
brane feeding of cultured gametocytes [52]. For in vitro
assays, salivary glands were hand dissected, collected in
Leibovitz culture medium (Sigma Aldrich) supplemented
with 10% foetal bovine serum (FBS, GIBCO), homoge-
nized in a homemade glass grinder. Sporozoites were
counted in a Bürker-Türk counting chamber using phase-
contrast microscopy.
Gliding assay
Gliding assays were performed in eight-chamber glass
Lab-Tek chamber slides (Nalgene, Nunc) pre-coated
with 25 μg/ml monoclonal anti-CSP (3SP2, [53]) to
capture shed P. falciparum circumsporozoite protein.
Sporozoites were pre-incubated in duplicate with 2 mg/ml
pre- or post-immunization IgG (due to limited plasma/
IgG availability) in the presence of 10% FBS for 30 min on
ice and then sporozoite/IgG suspension (30,000 spz/well)
was added to each well. After 90 min of incubation at 37°C
in 5% CO2, gliding trails were fixed with 4% paraformalde-
hyde (PFA) for 20 min at room temperature (RT). Each
well was washed twice with PBS, blocked with 10% FBS in
PBS for 20 min at RT and washed again. Gliding trails were
visualized with 10 μg/ml anti-CSP-FITC in 10% FBS in
PBS, incubated for 60 min in the dark at RT, washed and
mounted with Fluoromount-G (Southern Biotech) and
24×50 mm cover glasses (VWR International). The num-
ber of gliding trails was counted per 280 fields of view
(per well) at an enlargement of 1,000× with oil immersion.
Traversal assay
The functional capacity of CPS-induced antibodies to
inhibit sporozoite traversal through human hepatocytes
in vitro was studied using an optimized flow cytometry
based version (Behet et al., manuscript in preparation)
of the dextran incorporation assay [2,54]. Only cells
traversed by sporozoites and, therefore, wounded, incorp-
orate dextran and the percent of dextran-positive cells can
be quantified with flow cytometry.
The HC-04 hepatocyte cell line (Homo sapiens HC-04,
MRA-975, deposited by Jetsumon Sattabongkot [55])
was obtained through the MR4 as part of the BEI Resour-
ces Repository (NIAID, NIH). Cells were cultured in
HC-04 cell culture medium, containing equal volumes
of F-12 Nutrient Mixture (GIBCO) and Minimal Essential
Medium (GIBCO) supplemented with 10% FBS (GIBCO)
and 1% penicillin/streptomycin (GIBCO), at 37°C in an
atmosphere of 5% CO2.
Plasmodium falciparum sporozoites were pre-incubated
with 10 mg/ml or 1 mg/ml IgG for 30 min on ice. Data
from 2 pre-immunization IgG samples from Study 1 were
lost for technical reasons. Sporozoites pre-treated with
1.25 μg/ml of the mycotoxin cytochalasin D [56] served as
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a positive control resulting in a mean traversal inhibition
of 93.1% and non-infected cells incubated with dextran
served as a background control.
Sporozoites (5.104) were added to 96-well plates con-
taining monolayers of 5.104 HC-04 hepatocytes in the
presence of 0.5 mg/ml fixable tetramethylrhodamine
dextran (10,000 MW, D1817, Invitrogen) in duplicates
or triplicates, centrifuged at 3,000 RPM for 10 min at RT
with a low brake (Eppendorf Centrifuge 5810 R) and incu-
bated for 2 h at 37°C in 5% CO2. After incubation, wells
were gently washed three times with PBS to remove extra-
cellular dextran, trypsinized with 0.05% Trypsin-EDTA
(GIBCO) for 5 min at RT, taken up in 10% FBS in PBS,
and centrifuged at 3,600 RPM for 5 min at RT (Eppendorf
Centrifuge 5415 D). Cells were re-suspended in 1% PFA in
PBS and stored at 4°C in the dark until flow cytometric
analysis on an ADP Cyan flow cytometer (Beckman
Coulter). Sporozoite traversal was corrected for back-
ground dextran incorporation and the percent inhibition
of traversal was calculated as follows: 1 – (average%
dextran-positive cells in post-immunization IgG cultures/
average% dextran-positive cells in pre-immunization IgG
cultures) × 100%.
Passive immunization of human liver-chimeric mice and
sporozoite challenge
Human liver-chimeric mice over-expressing urokinase-
type plasminogen activator on a severe combined im-
munodeficiency background (uPA+/+-SCID mice) were
generated as previously described [57,58]. Cryopreserved
primary human hepatocytes (±1.106 cells/mouse, all
from the same donor and purchased from BD Gentest
(Erembodegem, Belgium) were injected in the spleens
of uPA+/+-SCID mice within two weeks after birth [57]. Hu-
man albumin levels were measured at different time points
after transplantation by using the Human Albumin ELISA
Quantitation kit (Bethyl Laboratories Inc., Montgomery,
TX). Mice with human albumin levels of >2 mg/ml were
considered successfully engrafted and used for infection
studies. All procedures were approved by the Animal
Ethics Committee of the Faculty of Medicine and Health
Sciences of the Ghent University (ECD 11/03).
The day before P. falciparum infection by mosquito bites,
human liver-chimeric mice were injected intraperitoneally
with 10 mg of post-immunization IgG from five sets of two
CPS-immunized volunteers per pool (Study 1) and six
CPS-immunized volunteers (Study 2). Each mouse was
injected with one IgG sample, and mice injected with pre-
immunization IgG served as controls. Mice were chal-
lenged by exposure to P. falciparum-infected mosquito
bites as previously described [58]. Briefly, the abdomen and
chest of mice were shaved with electric clippers and subse-
quently, mice were positioned on a cardboard box contain-
ing 20 P. falciparum-infected mosquitoes (one mouse per
box) and exposed for 20 minutes to infectious mosquito
bites. Successful blood feeding (median: 16 mosquitoes)
and sporozoite presence (100%) was confirmed by mos-
quito dissection after the challenge experiment [59,60].
Due to limited availability of liver-chimeric mice, each
IgG sample was injected in one mouse. The relatively
wide range in liver load in control mice receiving only
infectious mosquito bites as described previously [58,61],
was also reflected in the present study in the group of mice
receiving pre-immunization IgG. This precludes paired
analysis of mice receiving pre- and post-immunization IgG
from the same donor, and only allows to compare the pre-
and post-immunization groups at group level.
Isolation of DNA and quantification of P. falciparum and
human hepatocyte DNA
Isolation of liver DNA and quantification of P. falciparum
and human hepatocyte DNA was performed as previously
described [58]. Briefly, five days after sporozoite challenge
mice were maximally bled and sacrificed by cervical
dislocation. The removed livers were cut into 12 standard-
ized sections and stored in RNALater (Ambion) at 4°C
until analysis. For DNA extraction, 25 mg (±0.1 mg) liver
tissue was taken from each section and P. falciparum,
mouse and human hepatocyte DNA levels were quan-
tified in a total of 300 mg of liver tissue (12 sections × 25
mg; ~25% of total liver) using a highly sensitive qPCR
assay, targeting Pf18SRNA and mouse and human prosta-
glandin E receptor (PTGER2) genes, respectively [58,62].
The quantification of the relative amount of human and
mouse hepatocytes in mixed liver tissues allowed us to
assess the repopulation of chimeric mouse livers with
human hepatocytes, and thus to express P. falciparum
liver infection as a number of parasites per 106 human
hepatocytes [58,63]. DNA extracts from titrated samples
of ring-stage P. falciparum-infected erythrocytes that were
spiked with extracted DNA from a uninfected humanized
liver, were used for preparation of P. falciparum standard
curves. Standard curves were prepared by DNA extraction
from a titration of defined numbers of human peripheral
mononuclear cells (PBMCs) and mouse splenocytes. Per-
centage calculation was verified by making various ratios
of mouse and human DNA extracts [58].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software version 5 (GraphPad Software Inc., California,
USA). For analysis of data of traversal experiments,
differences between the percentage of dextran-positive
cells in pre- and post-immunization samples were tested
using the paired Student’s t-test. Statistical analysis of
humanized mouse data was performed using the non-
paired, non-parametric Mann Whitney U-test. A p-value
of <0.05 was considered significant.
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Results
Sporozoite gliding motility is not consistently reduced by
low IgG concentrations of CPS-induced antibodies
To explore the capacity of CPS-induced antibodies to
interfere with in vitro sporozoite gliding motility, sporozo-
ite gliding trails produced by P. falciparum sporozoites
pre-incubated with 2 mg/ml of either pre- or post-
immunization IgG from five pools of two volunteers
each (Study 1) or individual IgG samples from six CPS-
immunized volunteers (Study 2), were counted by micros-
copy. In vitro sporozoite gliding motility tested was highly
variable, not only between volunteers, but also between
replicates (Figure 1). In the presence of 2 mg/ml post-
immunization IgG, the number of gliding trails was
reduced in 3 out of 11 samples (n = 1 from Study 1 (Pool 5),
and n = 2 from Study 2 (Volunteers 1 and 3); Figure 1),
but in the majority of the volunteers no effect could
be observed.
Sporozoite traversal is dose-dependently inhibited by
CPS-induced antibodies
Subsequently, the inhibitory activity of immunization-
induced antibodies on in vitro hepatocyte traversal by spo-
rozoites was investigated. The percentage cells traversed
by sporozoites pre-incubated with two concentrations
(1 or 10 mg/ml) of either pre- or post-immunization
IgG from three pools of two CPS-immunized volunteers
each (Study 1) and six individual CPS-immunized volun-
teers (Study 2), was determined by flow cytometry
(Figure 2A and Additional file 1A and B). Pre-treatment
of sporozoites with 10 mg/ml post-immunization IgG
from both Study 1 and Study 2 lead to a statistically
significant reduction in in vitro hepatocyte traversal for all
volunteers, compared to pre-immunization IgG treatment
(Figure 2B and C; Study 1, p = 0.047; Study 2, p = 0.007).
The mean percent traversal inhibition by 10 mg/ml IgG
was 36.7% (p = 0.002; 50.5% (range 31.4-70.5%) and 29.8%
(range 9.7-54.6%) for Study 1 and 2, respectively). Tra-
versal inhibition was concentration-dependent, and sig-
nificantly higher for 10 mg/ml compared to 1 mg/ml IgG
(p = 0.005; Figure 2D). Nevertheless, even as little as 1
mg/ml post-immunization IgG resulted in a significant
inhibition of sporozoite traversal (p = 0.003) of 16.2%
(mean; range 1.6-45.5%; Figure 1D). Although the per-
centage of traversed cells varied between experiments with
individual mosquito and sporozoite batches (Figure 2B
and C), the variability between duplicate/triplicate mea-
surements within each experiment for each IgG sample
was very low (Additional file 1A and B; 1 mg/ml IgG and
10 mg/ml IgG, respectively).
Functional CPS-induced antibodies inhibit in vivo
sporozoite infection of the liver
Finally, it was investigated whether in vitro inhibitory
activity of CPS-induced IgG on sporozoite traversal
would translate into inhibition of sporozoite infection of
and/or development in the liver in vivo, using human
liver-chimeric mice infected with P. falciparum sporozo-
ites by mosquito bites. In two independent experiments,
mice were passively immunized with 10 mg of either
pre- or post-immunization IgG from five pools of
two volunteers each (Study 1) and six individual CPS-
immunized volunteers (Study 2) the day before challenge
infection. qPCR analysis was performed on liver sections
Figure 1 Effect of CPS-induced IgG on in vitro sporozoite gliding motility. The number of sporozoite gliding trails produced by sporozoites
incubated with 2 mg/ml IgG was counted in 280 fields per well at an enlargement of 1,000× with oil immersion. Incubations were performed in
duplicates and data are expressed as median with range. Pre- or post-immunization IgG samples from five pools of two volunteers each (Study 1)
or from six volunteers (Study 2), immunized by ChemoProphylaxis and Sporozoites immunization (CPS), were tested in 3 independent experiments in
duplicate. Black squares and grey circles represent the number of gliding trails produced by sporozoites incubated with pre- or post-immunization IgG,
respectively. Filled symbols show volunteers protected against mosquito challenge. Open symbols represent volunteers with unknown protection
status regarding mosquito challenge (blood-stage challenged).
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from all mice to determine the liver parasite burden after
five days to allow full liver-stage development of P. falcip-
arum parasites. The two groups of mice receiving pre- or
post-immunization IgG had comparable levels of repopu-
lation with human hepatocytes and body weight, and there
was no statistically significant difference in the number
of mosquitoes fed on both groups of mice (Table 1),
nor between the two experiments conducted.
Passive immunization of liver humanized uPA+/+-SCID
mice with post-immunization IgG one day prior to mos-
quito bite challenge significantly reduced the number of
infected hepatocytes by day 5 of infection (Table 1). The
median number of liver sections positive for P. falciparum
infection (Pf+) was significantly higher for mice injected
with pre- (median 5 Pf+ liver sections, interquartile range
(IQR) 4–10) than with post-immunization IgG (median 3
Pf+ liver sections, IQR 2–3; p = 0.003) and did not statisti-
cally differ between Study 1 and 2 samples. Additionally,
the median number of P. falciparum parasites per million
human hepatocytes in mice injected with either pre- or
post-immunization IgG was 326.5 (IQR: 209.3- 354.5) and
29.2 (IQR: 19.30-60.90), respectively and did not differ
between Study 1 and 2 samples. The reduction of the
median liver load by post-immunization IgG was 91.05%,
comparing the two groups of mice (n = 11 each) receiving
post-immunization or pre-immunization IgG (p = 0.0008).
Discussion
This study demonstrates for the first time that anti-
bodies with inhibitory activity against pre-erythrocytic
Figure 2 Effect of CPS-induced IgG on in vitro hepatocyte traversal. (A) The proportion of traversed (wounded) cells was determined by
flow cytometric analysis, after gating out debris and doublets. Sporozoites with dextran only were used as a positive control and sporozoites
pre-treated with cytochalasin D (cytoD) and dextran, as a negative control. Cells incubated with dextran only were used to correct for background.
(B) Sporozoites were pre-incubated with 10 mg/ml pre- or post-immunization IgG from three pools of two volunteers each (Study 1) or (C) from six
individual volunteers (Study 2), all of which underwent ChemoProphylaxis and Sporozoites immunization (CPS). Samples were tested in 4 experiments
with 3 mosquito batches, in duplicate or triplicates. (D) The percentage inhibition of traversal was calculated for post- compared to pre-immunization
IgG for each pool/volunteer at a concentration of either 1 or 10 mg/ml. Data are shown as the mean of duplicate or triplicate measurements, and
presented as circles or squares for Study 1 and 2, respectively. Filled symbols show volunteers protected against mosquito challenge. Open symbols
represent volunteers with unknown protection status regarding mosquito challenge (blood-stage challenged). Differences between pre- and
post-immunization IgG, and 1 and 10 mg/ml IgG was tested using the paired Student’s t-test.
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stages of P. falciparum are induced in human volunteers
that have undergone CPS-immunization.
The most striking result was that CPS-induced anti-
bodies could strongly reduce the liver parasite load in
human liver-chimeric mice, measured five days after infec-
tion by mosquito bite with P. falciparum sporozoites. This
strong reduction in late stage liver infection (91.05%)
might be explained by CPS-induced antibodies targeting
sporozoites either in the skin, in the circulation, or during
liver infection and/or development. In rodent malaria
models, it has been demonstrated that mice immunized
by gamma-irradiated Plasmodium berghei-infected mos-
quito bites exhibited high levels of anti-sporozoite
antibodies that immobilize sporozoites in the skin by
inhibiting their gliding motility and ability to invade
dermal blood vessels [64-66]. Therefore, CPS-induced
antibodies might also limit the numbers of sporozoites
injected into passively immunized mice and immobilizing
Table 1 Reduction of liver parasite burden by CPS-induced antibodies
Mouse
ID
IgG
sample ID
Time
point
Human
albumin levels
(mg/ml)
Proportion of
HuHEPb in
mouse liver (%)
Weight
mice
(g)
Number of
fed mosquitoes
(out of 20)
Liver parasite
burden
(No. Pf/10^6 HuHEP)
No. of Pf c positive
liver sections
(out of 12)
Pre-CPSa IgG
Study 1 B730R Pool 1 Pre 2,4 26,0 15,9 14 326,5 10
K1596RL Pool 2 Pre 2,6 37,2 11,5 19 209,3 5
B749RL Pool 3 Pre 3,0 39,7 12,1 17 77,2 5
K1589R Pool 4 Pre 4,0 33,0 12,5 14 280,1 11
K1576 Pool 5 Pre 3,1 35,0 12,2 20 373,0 10
Median 3,0 35,0 12,2 17 280,1 10
Study 2 K1630LR Vol.d 1 Pre 3,0 40,1 15,1 16 354,5 7
B934R Vol. 2 Pre 2,2 29,1 11,7 18 329,8 4
B934LR Vol. 3 Pre 2,6 37,7 12,8 17 37,6 3
B934L Vol. 4 Pre 1,7 28,5 9,6 12 463,1 4
K1575 Vol. 5 Pre 1,8 34,4 17,3 15 342,1 2
B881R Vol. 7 Pre 2,2 33,0 8,4 13 300,3 8
Median 2,2 33,7 12,3 16 336,0 4
Median Pre-CPS IgG Study 1 and 2: 2,6 34,4 12,2 16 326,5 5
Post-CPS IgG
Study 1 K1577L Pool 1 Post 1,9 29,2 15 16 90,5 1
K1540L Pool 2 Post 2,6 31,6 12,6 18 13,1 3
B733 Pool 3 Post 5,2 40,8 6,7 16 46,4 2
K1589 Pool 4 Post 4,5 35,9 13,1 15 20,8 3
B750L Pool 5 Post 2,5 33,4 12,2 16 302,6 6
Median 2,6 33,4 12,6 16 46,4 3
Study 2 K1666L Vol. 1 Post 4,6 41,0 15,7 14 37,1 3
B934 Vol. 2 Post 1,8 17,4 11,7 16 6,7 1
B905 Vol. 3 Post 4,2 41,2 12,7 18 28,3 2
K1630L Vol. 4 Post 1,7 21,2 14,6 14 60,9 2
B865 Vol. 5 Post 2,3 36,5 17,3 14 29,2 3
K1683 Vol. 7 Post 2,3 31,3 9,7 15 19,3 3
Median 2,3 33,9 13,7 15 28,8 3
Median Post-CPS IgG Study 1 and 2: 2,5 33,4 12,7 16 29,2 3
Significant difference Post- versus
Pre-CPS IgGe
ns ns ns ns p = 0.0008 p = 0.003
aCPS ChemoProphylaxis and Sporozoites immunization.
bHuHEP human hepatocytes.
cPf P. falciparum.
dVol. volunteer.
eStatistics: significant difference between Post- and Pre-CPS IgG calculated using the non-parametric Mann–Whitney U-test.
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the sporozoites in the mouse skin, thereby preventing
their journey to the liver in the first place. However, the
prolonged presence or trapping of sporozoites in the skin
after mosquito bites has only been demonstrated in
animal models of malaria and not in humans; this may be
different for humans. To assess the effect of CPS-induced
antibodies on sporozoite ejection during mosquito saliva-
tion and sporozoite motility in the skin, in vitro mosquito
salivation assays [66] and in vivo intravital microscopy
with Green-Fluorescent Protein-expressing P. falciparum
parasites [64] can be used, respectively.
The overall liver parasite burden of the control mice
(receiving pre-immunization IgG) was lower compared
to previous studies [58,61], likely due to mosquito and
sporozoite batch variations. Another likely source of
variation is the number of injected sporozoites between
mice. Nevertheless, the obtained data were consistent
across two independent experiments, and the data be-
tween two groups of mice receiving either pre- or post-
immunization IgG were comparable. Finally, while mice
injected with PBS could not be directly included in the
IgG experiments due to limited availability of chimeric
mouse numbers, PBS-injected mice used in other parallel
experiments performed in the same time frame showed
the same range in liver parasite burden as mice receiving
pre-immunization IgG (Additional file 2).
In vitro sporozoite gliding was inhibited by post-
immunization IgG in only 3/11 volunteers. This low fre-
quency may be due to the low concentration of IgG that
had to be used because of limited supply (2 mg/ml, i.e.
2–5 fold lower than the typical concentration in human
plasma). The high intra- and inter-assay variability, des-
pite the fact that always the same operator was carrying
out the experiments, may also have contributed to this
outcome, which is possibly due to variation between
sporozoite batches or methodological factors (e.g. the lack
of a centrifugation step to settle sporozoites prior to glid-
ing). Moreover, the manual readout by microscopy asses-
sing shape or length of gliding trails remains somewhat
subjective [67]. Overall, this assay appears more suitable
for qualitative rather than quantitative analysis, e.g. for
studying the phenotype of knock-out parasites [68,69].
The in vitro traversal assay, in contrast, is a high-
throughput assay and the variation between replicate
measurements is very tight (Additional file 1A and B).
Although the percentage cells traversed varied between
experiments (probably due to variation between sporo-
zoite batches), incubation of sporozoites with 10 μg/ml
of the anti-CSP monoclonal antibody (3SP2) consistently
results in the same proportional traversal inhibition
(median 86.4%; IQR 85.0-89.7%), independent of abso-
lute traversal rates (Additional file 3). Moreover, the vari-
ability between duplicate/triplicate measurements for each
IgG sample was very low. In contrast to the gliding assay,
significant and consistent inhibition of traversal activity of
sporozoites by CPS-induced antibodies was found, by as
little as 1 mg/ml post-immunization IgG. For three of the
volunteers whose IgG was assessed in this study, the
protection status against mosquito-bite challenge remains
unknown since they received a blood-stage challenge, but
they did undergo the same immunization regimen as pro-
tected volunteers [46]. Consistent with this, their ability to
reduce sporozoite traversal was comparable to that of
volunteers known to be protected from mosquito chal-
lenge, and 2/3 blood-stage challenged volunteers also
showed inhibition of gliding motility.
A dose-dependency for the traversal inhibitory effect
of CPS-induced IgG was observed, since traversal inhib-
ition by 10 mg/ml IgG was about 2.2 fold higher than
for 1 mg/ml. Traversal inhibition showed a broad range
across all volunteers. Possible reasons for this may be
the intra-individual differences in antibody specificity,
affinity maturation and/or binding capacity to sporozoites.
Of note, inhibition of sporozoite traversal in vitro did not
reach 100 percent, when using an average plasma concen-
tration of 10 mg/ml IgG, and was lower than the inhib-
ition of liver-stage infection and/or development in vivo.
This might be due to the fact that antibodies do not only
interfere with sporozoite hepatocyte traversal, but also
with other mechanisms of sporozoite functionality. An-
other targeted pathway might be hepatocyte invasion, as
shown for plasma from RAS- or CPS-immunized mice
[36], and for serum, IgG, or monoclonal antibodies de-
rived from human volunteers immunized by RAS [37-39],
an irradiated and cryopreserved sporozoite vaccine [40],
GAP ([43], or subunit vaccines [61,70] - although it is not
clear whether this process can be affected completely
independently from traversal, which is a requirement for
invasion [71]. Additionally, CPS-induced antibodies might
also interfere with intrahepatic parasite development by
inducing clearance of infected hepatocytes by means of
antibody-dependent cell-mediated cytotoxicity, as shown
in vitro in murine hepatic cells incubated with a monoclo-
nal antibody recognizing Plasmodium heat shock protein
70 [72,73]. SCID mice, while devoid of adaptive lym-
phocytes, still have an innate immune system including
natural killer (NK) cells and macrophages [74,75], both of
which are capable of mediating antibody-dependent killing
[76]. Whether such a mechanism may also play a role in
the in vivo liver-chimeric uPA+/+-SCID model remains to
be investigated.
Determining the antigen targets of CPS-induced func-
tional antibodies will help to shed further light on the
developmental stage at which the sporozoite/liver-stage
is targeted. CSP and LSA-1 antigens have previously
been demonstrated to be predominantly recognized by
CPS-induced antibodies, as shown by microarray analysis
of 809 P. falciparum antigens [48] and enzyme-linked
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immunosorbent assay and ELISpot analysis (Nahrendorf
and Scholzen et al., manuscript in preparation). RTS,S
vaccination has been shown to elicit antibody titers
against only CSP and the highest anti-CSP antibody titers
were found in protected volunteers [18,20,21,25]. Other
studies, however, found that antibody responses to both
CSP and TRAP did not differ between protected and
unprotected RAS-immunized volunteers, but protected
volunteers were able to recognize novel P. falciparum an-
tigens [77,78]. Taken together, this suggests that reactivity
of antibodies to pre-erythrocytic or cross-stage antigens
other than CSP or TRAP may be associated with protect-
ive immunity and, therefore, analysis of plasma samples
from (partially) protected CPS-immunized volunteers with
a microarray containing ~3,000 P. falciparum genes is
currently underway. This will be essential to identify novel
pre-erythrocytic antigens that are associated with func-
tional activity of CPS-induced antibodies and protective
immunity.
Importantly, liver-stage infection in liver-chimeric
uPA+/+-SCID mice was not completely blocked when
using 10 mg/ml IgG (which is equivalent to the typical
IgG concentration in human plasma). This indicates that
in CPS-immunized volunteers, other immune effector
mechanisms may contribute to parasite elimination in
concert with antibodies. CPS-induced antibodies may not
fully prevent parasite infection, but may reduce the liver
parasite load to such a extent, that T-cell mediated re-
sponses, for instance, might eliminate the residual infected
hepatocytes and thus, prevent blood-stage infection, as
observed in previous CPS-trials [45,47].
Conclusions
In conclusion, CPS-induced antibodies have functional
inhibitory activity against pre-erythrocytic stages of P.
falciparum by inhibiting sporozoite traversal in vitro
and infection of hepatocytes in vivo. These findings
highlight the importance of functional antibodies in
pre-erythrocytic immunity against malaria and are essen-
tial to the current understanding of the mechanisms
involved in pre-erythrocytic immunity. Open questions
based on these findings that will be addressed in future
studies, include the specificity of CPS-induced antibodies
and whether their functional activity correlates with CPS-
induced protection against malaria.
Additional files
Additional file 1: Replicates from in vitro traversal experiments.
Replicates from traversal experiments conducted with either 1 mg/ml (A) or
10 mg/ml (B) of pre- or post-immunization IgG from three pools of two
volunteers (Study 1) or six individual volunteers (Study 2) are shown. Data are
expressed as the mean percentage cells traversed ± SD. Black squares and
grey circles represent the percentage cells traversed by sporozoites incubated
with either pre-immunization or post-immunization IgG, respectively. Filled
symbols show volunteers protected against mosquito challenge. Open
symbols represent volunteers with unknown protection status regarding
mosquito challenge (blood-stage challenged).
Additional file 2: In vivomosquito bite challenge experiments in
human liver-chimeric mice. Data from human liver-chimeric mouse
experiments conducted with 10 mg of pre- or post-immunization IgG are
shown. Mice injected with PBS could not be directly included in the IgG
experiments due to limited availability of chimeric mouse numbers,
however, PBS-injected mice used in other parallel experiments performed in
the same time frame showed the same range in liver parasite burden as
mice receiving pre-immunization IgG. Data are expressed as the median
parasite load per million human hepatocytes ± interquartile range.
Additional file 3: Sporozoites incubated with or without 10 µg/ml
anti-CSP antibody. Data from 4 independent traversal experiments
conducted with or without 10 μg/ml of monoclonal anti-CSP antibody are
shown. (A) Data are expressed as the mean percentage cells traversed. Black
circles and squares represent the percentage cells traversed by sporozoites
incubated without or with 10 μg/ml anti-CSP antibody, respectively. (B) The
percentage inhibition of traversal was calculated for sporozoites only
compared to sporozoites incubated with 10 μg/ml anti-CSP antibody. Data are
expressed as the median percentage traversal inhibition ± interquartile range.
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